ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Dimension Links With Bayer For Hemophilia

by Michael McCoy
June 30, 2014 | APPEARED IN VOLUME 92, ISSUE 26

Dimension Therapeutics will work with Bayer HealthCare to develop a gene therapy for the treatment of hemophilia A based on Dimension’s adeno-associated virus technology. Dimension says its technology delivers the clotting factor gene, resulting in long-lasting expression of blood-clotting protein. Dimension, based in Cambridge, Mass., will receive $20 million up front from Bayer and could get milestone payments of up to $232 million. Separately, Dimension closed a financing round in which it raised $30 million.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment